Since its founding on 16th of April 2016 the Austrian Biosimilar Association follows the function of providing information about biosimilars. It also advocates for fair and sustainable competitive conditions for biosimilars in Austria. Biosimilars play an important role in the treatment of serious diseases (cancer, autoimmune and metabolic diseases). They are relevant for a wide patient access to innovative treatments and affect the general reliability of supply. On the other side the implementation of biosimilars also exerted a dampening effect on costs in the Austrian pharmaceutical and healthcare market. That supports our healthcare system to remain fundable.
16. April 2020
Happy 4th Anniversary Austrian Biosimilar Association